Q1 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
XXB750 - NPR1 agonist
NCT05562934 (CXXB750B12201)
Conclusions
Indication
Hypertension
Phase
Phase 2b
Patients
170
Primary
Outcome
Measures
Change from baseline in mean 24hr ambulatory systolic blood pressure at
week 12
Arms
Intervention
Arm 1 experimental: Dose 1
Arm 2 experimental: Dose 2
Arm 3 experimental: Dose 3
Arm 4 experimental: Dose 4
Arm 5 placebo comparator
Resistant Hypertension Patients
Target
Patients
Readout
Milestone(s)
2024
Publication
TBD
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
References
Abbreviations
Other
52 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation